TaiMed Biologics Inc.
Quick facts
Phase 3 pipeline
- ibalizumab-uiyk · Infectious Disease
Ibalizumab-uiyk is a monoclonal antibody that binds to the CD4 receptor on T cells, preventing HIV entry and replication.
Phase 2 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about TaiMed Biologics Inc.
What is TaiMed Biologics Inc.'s pipeline?
TaiMed Biologics Inc. has 1 drugs in Phase 3, 2 in Phase 2, 0 in Phase 1. Late-stage candidates include ibalizumab-uiyk.
Related
- Sector hub: All tracked pharma companies